Given their role in allergic and autoimmune diseases, Th2 cells are considered potential therapeutic targets. Strategies to modulate Th2 cell activity include the use of cytokine inhibitors, monoclonal antibodies targeting IL-4 and IL-13, and small molecule inhibitors. These approaches aim to reduce the pathological effects of Th2 cells while preserving their beneficial roles in immune defense.
